Hansa Biopharma announces reimbursement in the Netherlands of Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients
· Idefirix[®][▼][ ] (imlifidase) for enabling kidney transplantation in highly sensitized patients is now reimbursable and available for use in the Netherlands · Idefirix[® ]is the first and only approved medicine by the European Commision for the desensitization of highly sensitized patients prior to kidney transplantation[1]Lund, Sweden, August 2, 2021. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), the pioneer in enzyme technology for rare immunological conditions, today announces that its first-in-class treatment Idefirix[®▼] (imlifidase) is, as of August 1, reimbursable and